Monoclonal Antibodies in Infectious Diseases: Clinical Pipeline in 2011

被引：23
作者：
ter Meulen, Jan [1 ]
机构：
[1] Merck Res Labs, West Point, PA 19486 USA
来源：
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2011年 / 25卷 / 04期
关键词：
Monoclonal antibodies; Infectious diseases; Pipeline; SYNCYTIAL VIRUS-DISEASE; CELLS; PROPHYLAXIS; PROTECTION; BACTERIAL; SAFETY;
D O I：
10.1016/j.idc.2011.07.006
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Of the more than 20 monoclonal antibodies (mAbs) generated to combat infectious diseases (ID) that are in clinical development in 2011, most are in phase 1 or 2 and are directed against either viruses or bacterial toxins. Several high-profile anti-ID mAbs have recently failed in clinical trials. Despite the advancement in recombinant engineering technologies, anti-ID mAbs have yet to deliver on their promise as "magic bullets," especially against nosocomial infections. A paradigm shift in favor of developing mAb combinations, which act synergistically with each other or with small molecule drugs, may be required to move the field forward.
引用
收藏
页码：789 / +
页数：15
相关论文
共 36 条
[1]   An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity [J].
Baer, Mark ;
Sawa, Teiji ;
Flynn, Peter ;
Luehrsen, Kenneth ;
Martinez, David ;
Wiener-Kronish, Jeanine P. ;
Yarranton, Geoffrey ;
Bebbington, Christopher .
INFECTION AND IMMUNITY, 2009, 77 (03) :1083-1090
[2]   Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants [J].
Bakker, ABH ;
Marissen, WE ;
Kramer, RA ;
Rice, AB ;
Weldon, WC ;
Niezgoda, M ;
Hanlon, CA ;
Thijsse, S ;
Backus, HHJ ;
de Kruif, J ;
Dietzschold, B ;
Rupprecht, CE ;
Goudsmit, J .
JOURNAL OF VIROLOGY, 2005, 79 (14) :9062-9068
[3]   Antibodies for the treatment of bacterial infections: current experience and future prospects [J].
Bebbington, Christopher ;
Yarranton, Geoffrey .
CURRENT OPINION IN BIOTECHNOLOGY, 2008, 19 (06) :613-619
[4]   Safety and Pharmacokinetics of Single Intravenous Dose of MGAWN1, a Novel Monoclonal Antibody to West Nile Virus [J].
Beigel, John H. ;
Nordstrom, Jeffrey L. ;
Pillemer, Stanley R. ;
Roncal, Cory ;
Goldwater, D. Ronald ;
Li, Hua ;
Holland, P. Chris ;
Johnson, Syd ;
Stein, Kathryn ;
Koenig, Scott .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) :2431-2436
[5]   Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus [J].
Broering, Teresa J. ;
Garrity, Kerry A. ;
Boatright, Naomi K. ;
Sloan, Susan E. ;
Sandor, Frantisek ;
Thomas, William D., Jr. ;
Szabo, Gyongyi ;
Finberg, Robert W. ;
Ambrosino, Donna M. ;
Babcock, Gregory J. .
JOURNAL OF VIROLOGY, 2009, 83 (23) :12473-12482
[6]   Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection [J].
Bruno, Christopher J. ;
Jacobson, Jeffrey M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (09) :1839-1841
[7]   Motavizumab [J].
Cingoz, Oya .
MABS, 2009, 1 (05) :439-442
[8]   A Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically Significant Congenital Heart Disease [J].
Feltes, Timothy F. ;
Sondheimer, Henry M. ;
Tulloh, Robert M. R. ;
Harris, Brian S. ;
Jensen, Kathryn M. ;
Losonsky, Genevieve A. ;
Griffin, M. Pamela .
PEDIATRIC RESEARCH, 2011, 70 (02) :186-191
[9]   Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine [J].
Kelly-Quintos, C ;
Cavacini, LA ;
Posner, MR ;
Goldmann, D ;
Pier, GB .
INFECTION AND IMMUNITY, 2006, 74 (05) :2742-2750
[10]   Respiratory syncytial virus disease: update on treatment and prevention [J].
Krilov, Leonard R. .
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (01) :27-32
1234